Clinical Trials

Leukemia, Lymphoma, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell

NCT01060384 2023-10-04

Study of Lenalidomide and Ofatumumab for the Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma

Phase 1/2 Completed

46 enrolled 8 charts

Lymphoma, Non-Hodgkin

NCT01294579 2018-08-09

Ofatumumab and Bendamustine Followed by Maintenance Ofatumumab for Rituximab Relapsed Indolent B-cell Non-Hodgkin's Lymphoma (B-NHL)

49 enrolled 13 charts

Lymphoma, Non-Hodgkin, Recurrence

NCT01200589 2018-05-16

HOMER

Phase 3 Terminated

438 enrolled 14 charts

Lymphoma, Non-Hodgkin

NCT01171378 2018-04-25

CHOP-OR

43 enrolled

Lymphoma, Non-Hodgkin

NCT01263418 2015-10-12

Ofatumumab In Older Patients With Untreated Low Or Intermediate Risk Indolent B-Cell Lymphomas

Phase 2 Withdrawn

Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Marginal Zone

NCT01119794 2015-08-26

Ofatumumab and Bortezomib for Patients With Low-grade B-cell Non-hodgkin Lymphoma That Relapse After Rituximab

Phase 2 Terminated

10 enrolled 7 charts

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Leukemia, B-Cell, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT00092274 2015-04-21

Study of HuMax-CD20, a New Drug to Treat Early Stage Non-Hodgkin´s Follicular Lymphoma

Phase 1/2 Withdrawn

Lymphoma, Follicular, Lymphoma, Non-Hodgkin

NCT00823719 2013-03-12

Phase II Study of Ofatumumab Plus Ifosfamide, Carboplatin, Etoposide (ICE) or Dexamethasone, Cytarabine, Cisplatin (DHAP) Chemotherapy Regimen in Relapsed/ Refractory Diffuse Large B Cell Lymphoma (DLBCL)

61 enrolled 25 charts

Lymphoma, Non-Hodgkin, Neoplasms, Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT01108341 2012-08-28

Study to Evaluate the Efficacy and Safety of Treatment With Bendamustine in Combination With Ofatumumab in Previously Untreated Patients With Indolent B-Cell Non-Hodgkin's Lymphoma (NHL)

50 enrolled 10 charts

Lymphoma, Non-Hodgkin

NCT01221103 2011-09-13

Dexamethasone, Ofatumumab and Bendamustine (DOT) First-line in Mantle-cell Lymphoma(MCL)

Phase 1/2 Unknown

50 enrolled

Lymphoma, Non-Hodgkin, Lymphoma, Mantle-Cell

NCT01125787 2011-07-20

Clinical Protocol for the Treatment of Patients With Previously Untreated Chronic Lymphocytic Leukemia With a Combination of Bendamustine and Ofatumumab

Phase 2 Terminated

1 enrolled

Leukemia, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Hematologic Neoplasms

NCT01131247 2011-07-20

PH2 Trial in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) With a Combination of Bendamustine & Ofatumumab

Phase 2 Withdrawn

37 enrolled